MedTrace Logo

Safety and Efficacy of Imiquimod Applied in Dose-Cycle for Actinic Keratoses

NCT00175643 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2006-05-09

No results posted yet for this study

Summary

It is believed that imiquimod 5% cream has the potential to be an effective treatment for actinic keratoses. The purpose of this study is to evaluate the duration of the effect of topical imiquimod 5% topical cream for the treatment of actinic keratoses.

Conditions

  • Actinic Keratoses

Interventions

DRUG

imiquimod

Sponsors & Collaborators

  • Vancouver Coastal Health Research Institute

    collaborator OTHER

  • 3M

    collaborator INDUSTRY

  • University of British Columbia

    lead OTHER

Principal Investigators

  • Jason K Rivers, M.D. · Division of Dermatology, University of British Columbia

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2005-02-28
Completion
2005-11-30

Countries

  • Canada

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00175643 on ClinicalTrials.gov